Skip to main content

Table 2 Population included in studies selected for meta-analysis

From: Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis

Author, study [reference]

Patients (n) and operations

LVEF cutoffs

Administration timing and dosages

Low LVEF only

 Erb et al., 2014 [19]

33 On-pump CABG (with or without valve)

<30%

Before incision 12.5-mg total dose at 0.1 μg∙kg−1∙minute−1

 Levin et al., 2012 [20]

252 On-pump CABG only

<25%

Preoperative 10-μg/kg bolus; 0.1 μg∙kg−1∙minute−1 for 23 h

 Mehta et al., 2017 [13]

849 On-pump cardiac surgery

<35%

Before incision 0.2 μg/kg/minute for 1 h; 0.1 μg∙kg−1∙minute−1 for 23 h

 Shah et al., 2014 [21]

50 Off-pump CABG only

<30%

Preoperative 0.133 μg∙kg−1∙minute−1 for 24 h

 Sharma et al., 2014 [22]

40 CABG and mitral valve repair

<30%

Preoperative 200 μg∙kg−1 for 24 h

 Lomivorotov et al., 2012a [17]

60 On-pump CABG only

<35%

Before incision 12-μg∙kg−1 bolus; 0.1 μg∙kg−1∙minute−1 for 24 h

LCOS only

–

–

–

–

Low LVEF and LCOS

   

 Landoni et al., 2017 [14]

504 All cardiac surgery

<25%/or LCOSb

Mainly postoperativeb 0.05 μg∙kg−1∙minute−1 for 48 h or until ICU discharge

  1. Abbreviations: CABG Coronary artery bypass grafting, LCOS Low cardiac output syndrome, LVEF Left ventricular ejection fraction
  2. The studies are classified according to the subgroup of low LVEF and/or LCOS. We also report the number of patients in each study, the timing of levosimendan (placebo) administration, and the outcomes of interest of our meta-analysis reported by each study
  3. aThe study of Lomivorotov et al. [17] was a three-arm study with patients with low LVEF receiving preoperative levosimendan and intra-aortic balloon pump (IABP) vs levosimendan alone vs IABP alone. The data from the first two groups were included in a sensitivity analysis
  4. bIn this trial, only 4% of patients were randomized according to a preoperative low LVEF, 19% according to the need for IABP, 12% for difficult weaning from cardiopulmonary bypass, and 65% for postoperative LCOS